Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
12.78
+0.20 (1.59%)
At close: Feb 9, 2026, 4:00 PM EST
12.78
0.00 (0.00%)
After-hours: Feb 9, 2026, 4:49 PM EST
Phathom Pharmaceuticals Revenue
Phathom Pharmaceuticals had revenue of $49.50M in the quarter ending September 30, 2025, with 202.74% growth. This brings the company's revenue in the last twelve months to $147.19M, up 460.30% year-over-year. In the year 2024, Phathom Pharmaceuticals had annual revenue of $55.25M with 8,001.47% growth.
Revenue (ttm)
$147.19M
Revenue Growth
+460.30%
P/S Ratio
6.17
Revenue / Employee
$344,707
Employees
427
Market Cap
1.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55.25M | 54.57M | 8,001.47% |
| Dec 31, 2023 | 682.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Iovance Biotherapeutics | 250.43M |
| Geron | 183.40M |
| ARS Pharmaceuticals | 142.77M |
| CytomX Therapeutics | 113.63M |
| UroGen Pharma | 96.52M |
| Vir Biotechnology | 16.86M |
| Nanobiotix | 11.93M |
| Aktis Oncology | 5.56M |
PHAT News
- 4 days ago - Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewsWire
- 4 weeks ago - Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth - Seeking Alpha
- 3 months ago - Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) - GlobeNewsWire
- 3 months ago - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript - Seeking Alpha